Immunitybio

Immunitybio R&D per Employee

The R&D Spending per Employee of Immunitybio (IBRX) as of Oct 5, 2026 is 300,832.13 USD. In the previous year, R&D Spending per Employee was 275,172.21 USD — a change of 9.33% (higher).

R&D per Employee

300,832.13USD

YoY

9.33%

Last updated:

R&D Spending per Employee of Immunitybio is 2026 300,832.13 USD. R&D Spending per Employee of Immunitybio was 2025 275,172.21 USD. It decreases by 9.33% higher compared to the previous year.

The Immunitybio R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
77,305.35 USD
Jan 1, 2019
70,745.30 USD
Jan 1, 2020
201,891.46 USD
Jan 1, 2021
283,586.11 USD
Jan 1, 2022
359,115.77 USD
Jan 1, 2023
336,274.96 USD
Jan 1, 2024
275,172.21 USD
Jan 1, 2025
300,832.13 USD
The Immunitybio R&D per Employee history
YEARR&D per EmployeeYoY
300,832.13USD+9.33%
275,172.21USD-18.17%
336,274.96USD-6.36%
359,115.77USD+26.63%
283,586.11USD+40.46%
201,891.46USD+185.38%
70,745.30USD-8.49%
77,305.35USD+34.29%
57,565.85USD+49.85%
38,416.79USD+132.17%
16,547.03USD+616.87%
2,308.25USD—
Access this data via the Eulerpool API

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunitybio stock

R&D Spending per Employee of Immunitybio is 300,832.13 USD in 2026.

R&D Spending per Employee of Immunitybio changed from 275,172.21 USD to 300,832.13 USD, representing a 9.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Immunitybio since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Immunitybio historically and in real time.

Access this data via the Eulerpool API

Workforce — Immunitybio

All Key Metrics — Immunitybio